Who needs an additional COVID-19 Vaccines?

    • CDC recommends that the following groups should receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series (i.e., the first 2 doses of a COVID-19 vaccine):
      • people aged 65 years and older
      • residents aged 18 years and older in long-term care settings
      • people aged 50–64 years with underlying medical conditions
    • CDC also recommends that the following groups may receive a booster shot of Pfizer-BioNTech’s COVID-19 Vaccine at least 6 months after completing their Pfizer-BioNTech primary series, based on their individual benefits and risks:
      • people aged 18–49 years with underlying medical conditions
      • people aged 18–64 years at increased risk for COVID-19 exposure and transmission because of occupational or institutional setting
    • These recommendations only apply to people who previously received a Pfizer-BioNTech primary series (i.e., the first 2 doses of a COVID-19 vaccine).
    • People can talk to their healthcare provider about whether getting a Pfizer-BioNTech COVID-19 booster shot is appropriate for them.

If I received the Moderna vaccine originally and am immunocompromised, will I need a booster shot?

    • Yes, an additional dose of either Pfizer or Moderna is recommended 6 months after completion of the first series (first and second doses).

If I received the J&J vaccine originally and am immunocompromised, will I need a booster shot?

    • Most likely, yes, but there aren’t enough data to determine if a J&J booster is necessary at this time. Once the CDC has collected enough data, a decision will be made.

If I received the Moderna or J&J vaccine originally and am not immunocompromised, can I receive a booster shot?

    • Booster shots for people who received Moderna or J&J for their primary series is not supported by data at this time and a booster should not be administered to these populations.

What are the risks of receiving an additional dose of vaccine?

      • There is currently limited information on the risks of receiving an additional dose of vaccine. the safety, efficacy, and benefit of an additional COVID-19 vaccine in those patients who are immunocompromised continues to be evaluated at this time; however, those who have received their third Pfizer or Moderna vaccine stat that the side effects are similar to those that they received after their second dose where fatigue and pain at the injection site were the most commonly reported side effects.

 

References:

COVID-19 vaccines for moderately to severely immunocompromised people. Centers for Disease Control and Prevention. https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/immuno.html. Accessed August 26, 2021.